Zum Inhalt

HealthOSArzneimittel

Arbeitsbereiche

Nachschlagen

Wirkstoffe & Arzneimittelsicherheit

Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.

Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.

RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.

Quellenpassagen (1)

Nebenwirkungen · Votrient

Votrient 200 mg film-coated tablets Votrient 400 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 15–16

HOS-122601 · Präparat HOS-095539

15 Very common Alanine 246 (21%) 84 (7%) 14 (1%) aminotransferase increased Aspartate 211 (18%) 51 (4%) 10 (<1%) aminotransferase increased Common Weight decreased 96 (8%) 7 (<1%) 0 Blood bilirubin 61 (5%) 6 (<1%) 1 (<1%) increased Blood creatinine 55 (5%) 3 (<1%) 0 increased Lipase increased 51 (4%) 21 (2%) 7 (<1%) White blood cell count 51 (4%) 3 (<1%) 0 decreasedd Blood thyroid 36 (3%) 0 0 stimulating hormone increased Amylase increased 35 (3%) 7 (<1%) 0 Gamma- 31 (3%) 9 (<1%) 4 (<1%) glutamyltransferase Investigations increased Blood pressure 15 (1%) 2 (<1%) 0 increased Blood urea increased 12 (1%) 1 (<1%) 0 Liver function test 12 (1%) 6 (<1%) 1 (<1%) abnormal Uncommon Hepatic enzyme 11 (<1%) 4 (<1%) 3 (<1%) increased Blood glucose 7 (<1%) 0 1 (<1%) decreased Electrocardiogram QT 7 (<1%) 2 (<1%) 0 prolonged Transaminase 7 (<1%) 1 (<1%) 0 increased Thyroid function test 3 (<1%) 0 0 abnormal Blood pressure 2 (<1%) 0 0 diastolic increased Blood pressure 1 (<1%) 0 0 systolic increased †Treatment-related adverse reaction reported during post-marketing period (spontaneous case reports and serious adverse reactions from all pazopanib clinical studies). *Treatment-related adverse reaction reported only during the post-marketing period. Frequency cannot be estimated from the available data. The following terms have been combined: a Abdominal pain, abdominal pain upper and abdominal pain lower b Oedema, oedema peripheral, eye oedema, localised oedema and face oedema c Dysgeusia, ageusia and hypogeusia d White cell count decreased, neutrophil count decreased and leukocyte count decreased e Decreased appetite and anorexia f Cardiac dysfunction, left ventricular dysfunction, cardiac failure and restrictive cardiomyopathy g Venous thromboembolic event, deep vein thrombosis, pulmonary embolism and thrombosis

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2025-10-28T11:24:00Z · SHA-256 38e00132fe316301c56a9c9a4f9247483c54b55dd743bedaab120a272380aaff · Passage d0d73005e7f5f9020cd8db2327489561a5d3a5c73a885ed6a99f38442188826b · Zeichen 16245–20407 im Abschnitt

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.